Sign in Subscribe
BioMed

🧬 BioMed Pulse · 2026-08-19 02:02 UTC

BIOMED PULSE

Daily Briefing on Longevity, Viruses & New Cures

Wednesday, August 19, 2026

⚡ TL;DR

The Bundibugyo virus Ebola outbreak in the Democratic Republic of the Congo has become the largest Ebola outbreak ever recorded, now in a phase of intense, sustained transmission across multiple provinces. The overall mood is urgent on the outbreak front, with cautious forward motion in longevity science around senescence, bone aging, and statin deprescribing evidence.

🦠 OUTBREAKS & VIRUSES

EBOLA (BUNDIBUGYO VIRUS) - DRC AND UGANDA: RECORD-BREAKING OUTBREAK

  • As of August 14, 2026, WHO's DON-615 describes the DRC Bundibugyo virus disease (BVD) outbreak as the largest Ebola outbreak ever reported in the country, expanding faster than any previous Ebola outbreak, with sustained transmission now spanning multiple provinces beyond the original Mongbwalu health zone in Ituri Province. [1]
  • The July 17 DON-613 update recorded a cumulative 2,124 confirmed cases including 828 deaths from DRC alone, with cross-border transmission to Uganda documented since the outbreak was declared May 15, 2026. [2]
  • The July 3 DON-612 update already showed 1,460 confirmed cases and 452 deaths as of July 1, illustrating the explosive acceleration in case counts over just six weeks. [3]
  • CDC mobilized an international response beginning May 17, 2026, and enhanced Ebola airport screening was activated at Washington Dulles International Airport on May 21 and subsequently expanded to Atlanta's Hartsfield-Jackson on May 23. [4] [5] [6]
  • The virus involved is Bundibugyo virus, a distinct Ebola species first identified in Uganda in 2007, which carries a case fatality rate historically lower than Zaire Ebola but is now driving unprecedented case counts. [7] [8]

ANDES HANTAVIRUS - M/V HONDIUS CRUISE SHIP, MULTI-COUNTRY

  • WHO's fifth DON (DON-611, July 2, 2026) on the Andes hantavirus (ANDV) outbreak linked to the cruise ship M/V Hondius confirmed ongoing multi-country case spread following the initial notification of severe acute respiratory illness cases onboard on May 2, 2026. [9]
  • Earlier updates confirmed at least two laboratory-confirmed ANDV cases and five suspected cases among 147 onboard passengers and crew by May 4, with additional confirmed cases reported in subsequent weeks through mid-June. [10]
  • Andes hantavirus causes hantavirus pulmonary syndrome (HPS), a severe respiratory illness with high mortality, and uniquely among hantaviruses can be transmitted person-to-person.
  • CDC provided rolling hantavirus response transcripts from May 13 through June 24, 2026, reflecting continued monitoring of exposed travelers.

CYCLOSPORA - TACO BELL ICEBERG LETTUCE, FIVE STATES

  • As of July 17, 2026, CDC identified shredded iceberg lettuce served at Taco Bell locations as the source of cyclosporiasis infections across five states, with 1,644 people reported sick.
  • The outbreak subsequently expanded to four new states by July 24, 2026, and CDC issued ongoing guidance for consumers and restaurant operators.
  • Cyclospora cayetanensis is a microscopic parasite causing watery diarrhea; it is not killed by standard sanitizers and requires extended cooking or treatment.

SALMONELLA - JALAPEÑOS, MULTISTATE

  • CDC issued a food safety alert on August 5, 2026, warning of a multistate Salmonella outbreak linked to jalapeños.

WEST NILE VIRUS - EARLY SEASON RECORD CASES

  • CDC flagged an early and record West Nile virus season as of July 1, 2026, urging Americans to use mosquito bite prevention especially over holiday weekends.

NIPAH VIRUS - INDIA (KERALA)

  • On June 11, 2026, Kerala State Health Department confirmed one laboratory-confirmed Nipah virus (NiV) case in Kozhikode district in an adult male who developed neurological symptoms on May 30, 2026, and was hospitalized June 10.
  • WHO's DON-609 assessed the risk from this isolated case as low at the national level given Kerala's established rapid NiV response protocols, but noted NiV's high fatality potential and lack of approved treatments.

YELLOW FEVER - GLOBAL ELEVATION

  • WHO DON-610 (June 24, 2026) reported that from January 1 to May 26, 2026, six countries recorded 79 human yellow fever infections, reflecting continued transmission activity in the Americas carried over from an elevated 2025 season.

MEASLES - BANGLADESH NATIONWIDE SURGE

  • WHO notified on April 23, 2026, of 19,161 suspected measles cases and 2,897 laboratory-confirmed cases across 58 of 64 districts in Bangladesh as of early April.
  • CDC separately reinforced a national U.S. measles response through state collaboration as of March 9, 2026, following the Texas outbreak earlier in the year that resulted in at least two deaths.
  • New CDC data released August 17, 2026, show kindergarten vaccination coverage remains high with only a 0.1% decline, a slight but notable downward shift during an active measles resurgence period.

AVIAN INFLUENZA A(H9N2) - ITALY

  • WHO DON-597 (April 10, 2026) reported a human case of H9N2 in an adult male in Italy returning from Senegal, confirmed by next-generation sequencing.

🧬 LONGEVITY & AGING

SENESCENCE AND OSTEOARTHRITIS: DUAL-MODAL ANTIOXIDANT PLUS EPIGENETIC APPROACH

  • A study published in Bioactive Materials (Europe PMC, July 31, 2026) describes a dual-modal strategy combining antioxidant activity and epigenetic modulation to interrupt the self-perpetuating senescence cycle in osteoarthritis cartilage, potentially halting joint aging at the cellular level.
  • Cellular senescence in joints creates a feedback loop where damaged cells secrete pro-inflammatory signals (the senescence-associated secretory phenotype, SASP) that push neighboring cells into senescence; this work targets that cycle simultaneously via two mechanisms.

BONE AGING: EGFR LOSS IN SKELETAL STEM CELLS IMPAIRS FRACTURE HEALING

  • Research published in Bioactive Materials (Europe PMC, August 4, 2026) found that loss of EGFR (epidermal growth factor receptor) activity in skeletal stem and progenitor cells is associated with impaired fracture healing in aged mice, offering a mechanistic explanation for why older bones heal more slowly.
  • The finding points to EGFR signaling as a potential therapeutic target to restore regenerative capacity in aged skeletal tissue.

BONE AGING: PUNICALAGIN AND SENILE OSTEOPOROSIS

  • A study in Regenerative Therapy (Europe PMC, July 25, 2026) found that punicalagin, a polyphenol from pomegranate, alleviates senile osteoporosis in experimental models by inhibiting senescence of bone mesenchymal stem cells through activation of the NRF2/HO-1 antioxidant pathway.
  • This adds punicalagin to a growing list of natural compounds under investigation as geroprotective agents targeting stem cell aging in bone.

STATIN DEPRESCRIBING IN OLDER ADULTS: KEY RANDOMIZED TRIAL

  • The SAGA/SITE trial, a multicentre open-label non-inferiority randomized trial published in Lancet Healthy Longevity, evaluated discontinuation of statins for primary prevention of atherosclerotic cardiovascular disease in adults aged 75 years or older.
  • An accompanying editorial in Lancet Healthy Longevity argues that the evidence calls for changing the conversation about statin use in older adults, moving away from automatic continuation toward individualized deprescribing discussions.

METFORMIN FOR PHYSICAL FUNCTION IN OLDER ADULTS WITH OBESITY: DEMFOS TRIAL

  • The DEMFOS randomized controlled trial published in Lancet Healthy Longevity tested metformin added to lifestyle intervention for physical function in older adults with obesity, finding modest benefit but prompting debate about inflated expectations for metformin as a geroprotective drug.
  • An accompanying commentary by Witham and McDonald in Lancet Healthy Longevity cautions against overstating metformin's frailty-prevention role based on these results.

TELOMERE REPAIR AND CANCER CELL AGING

  • A study in Nucleus (Europe PMC, July 23, 2026) by Salmina and colleagues examined repair and misrepair of telomeric DNA in doxorubicin-treated cancer cells, with a focus on dynamic interactions with PML nuclear bodies and lamin B1, structures central to nuclear architecture and aging-related genome instability.

POSITIVE LIFE ORIENTATION AND BLOOD PRESSURE IN AGING

  • Research in Blood Pressure (Europe PMC, August 7, 2026) using two Finnish generational cohorts born 20 years apart found that positive life orientation is associated with lower blood pressure in older adults, adding psychosocial factors to the established roster of cardiovascular aging modulators.

DIET AND EPIGENETIC AGING IN DOGS: PILOT STUDY

  • A pilot study in Veterinary Record Open (Europe PMC, August 5, 2026) found that a minimally processed, human-grade diet altered canine epigenetic aging markers, raising interest in diet-epigenome interactions as a model for studying nutritional geroprotection.

SLEEP AND AGING: PEPTISLEEP PILOT

  • A randomized, placebo-controlled pilot study in Sleep Medicine X (Europe PMC, July 28, 2026) tested PeptiSleep, a peptide supplement, for sleep modification and biometric outcomes in adults with sleep impairment, reporting beneficial sleep changes compared to placebo.

METABOLIC LIVER DISEASE AND LYSOSOMAL AMPK ACTIVATION

  • Research in Bioactive Materials (Europe PMC, July 12, 2026) reports that targeting ROAM1 with UDP-GlcNAc nanosheets selectively activates lysosomal AMPK to resolve metabolic dysfunction-associated steatotic liver disease (MASLD), a condition strongly linked to aging-related metabolic decline.

💊 NEW CURES & APPROVALS

WINREVAIR (SOTATERCEPT-CSRK) - MERCK SHARP DOHME, SUPPLEMENTAL APPROVAL

  • Merck Sharp and Dohme received a supplemental approval (SUPPL AP) for Winrevair (sotatercept-csrk, BLA761363), an activin signaling inhibitor approved for pulmonary arterial hypertension (PAH), reflecting expanded or updated labeling.
  • Sotatercept works by acting as a ligand trap for TGF-beta superfamily members, reducing the pathological vascular remodeling that drives PAH progression.

OPDIVO (NIVOLUMAB) - BRISTOL MYERS SQUIBB, SUPPLEMENTAL APPROVAL

  • Bristol Myers Squibb received a supplemental approval for Opdivo (nivolumab, BLA125554), the PD-1 checkpoint inhibitor with broad oncology indications, reflecting a new indication or updated labeling.

FOSFOMYCIN TROMETHAMINE - NOVITIUM PHARMA, ORIGINAL APPROVAL

  • Novitium Pharma received an original approval (ORIG AP, ANDA210426) for fosfomycin tromethamine, an antibiotic used to treat uncomplicated urinary tract infections, expanding the generic supply of this drug.

FIDAXOMICIN - SANDOZ, ORIGINAL GENERIC APPROVAL

  • Sandoz received an original generic approval (ORIG AP, ANDA220465) for fidaxomicin, a narrow-spectrum macrolide antibiotic used to treat Clostridioides difficile infections, expanding access to a drug critical in aging and hospital populations.

HEPZATO (MELPHALAN HYDROCHLORIDE) - DELCATH SYSTEMS INC, SUPPLEMENTAL APPROVAL

  • Delcath Systems received a supplemental approval for Hepzato (melphalan hydrochloride, NDA201848), a hepatic delivery system for treating uveal melanoma metastatic to the liver.

METFORMIN HYDROCHLORIDE - MULTIPLE GENERIC SPONSORS

  • Supplemental approvals for metformin hydrochloride were recorded for Barr (ANDA076863), Granules India (ANDA090564), Marksans Pharma (ANDA090888), Mylan (ANDA075973), Chartwell (ANDA075972), and Ajanta Pharma (ANDA213651), maintaining a robust generic supply of the foundational type 2 diabetes and longevity-studied drug.

🧪 CLINICAL TRIALS

AMYLOID PET IMAGING IN THE BALTIMORE LONGITUDINAL STUDY OF AGING (NCT07099053)

  • A new trial registered August 18, 2026, uses amyloid PET imaging to track amyloid protein accumulation in the brains of participants in the long-running Baltimore Longitudinal Study of Aging, aiming to understand the trajectory of amyloid buildup in cognitively normal aging adults before dementia onset.

MIRDAMETINIB PLUS SIROLIMUS FOR RAS-MUTATED RELAPSED/REFRACTORY MULTIPLE MYELOMA (NCT06876142)

  • A trial registered August 18, 2026, combines mirdametinib (MEK inhibitor) and sirolimus (mTOR inhibitor) for patients with KRAS- or NRAS-mutated relapsed/refractory multiple myeloma, targeting the RAS/MAPK and mTOR pathways simultaneously in a cancer population predominantly older adults.

DHA-TAURINE METABOLIC ABSORPTION STUDY (NCT07771309)

  • A trial registered August 18, 2026, investigates the metabolic absorption rates of DHA-taurine as an omega-3 fatty acid source in individuals with impaired fat digestion, addressing a known gap in cardiometabolic supplement efficacy in older adults with gastrointestinal conditions.

SIBEPRENLIMAB IN PEDIATRIC IgA NEPHROPATHY - PHASE 3 (NCT07770815)

  • A Phase 3 open-label trial registered August 18, 2026, will evaluate sibeprenlimab, a monoclonal antibody targeting APRIL (a proliferation-inducing ligand), administered subcutaneously every 4 weeks in children aged 2 to 17 with IgA nephropathy.

PROSTATE CANCER IMMUNOTHERAPY VACCINE WITH IL-15 SUPERAGONIST (NCT07574541)

  • A trial registered August 18, 2026, tests a multitargeted recombinant adenovirus 5 vaccine (TriAdeno) targeting PSA, MUC-1, and brachyury combined with the IL-15 superagonist N-803 in men with clinically localized prostate cancer on active surveillance, aiming to stimulate immune clearance and delay progression.

LEAD-212 RADIOLIGAND THERAPY FOR SOMATOSTATIN RECEPTOR-POSITIVE TUMORS (NCT06427798)

  • A trial registered August 18, 2026, evaluates [212Pb]VMT-alpha-NET, a lead-212-labeled alpha-particle radioligand, in patients with metastatic or inoperable SSTR-positive gastrointestinal neuroendocrine tumors and pheochromocytoma/paraganglioma who have already received systemic radioligand therapy, targeting a refractory older-skewing cancer population.

PROCALCITONIN AS PROGNOSTIC MARKER IN OLDER HOSPITALIZED PATIENTS (NCT07770334)

  • A trial registered August 18, 2026, examines procalcitonin as a prognostic predictor specifically in older adults hospitalized with acute infectious disease in an internal medicine setting, addressing a notable evidence gap since most prior procalcitonin data come from younger ICU patients.

📢 PUBLIC HEALTH

DRUG-RESISTANT BACTERIA SHARP RISE

  • A CDC report released September 23, 2025, found a dramatic increase in a dangerous type of drug-resistant bacteria in the United States, reinforcing antimicrobial resistance as a growing public health emergency.

KINDERGARTEN VACCINATION RATES - SLIGHT DECLINE FLAGGED

  • CDC data released August 17, 2026, show a 0.1% decline in kindergarten vaccination coverage, a small but concerning downward shift during an active year for vaccine-preventable disease including measles.

CONGENITAL SYPHILIS - 12TH CONSECUTIVE ANNUAL INCREASE

  • New CDC data released September 24, 2025, showed U.S. cases of congenital syphilis increased for the 12th consecutive year in 2024, underscoring persistent gaps in prenatal STI screening and treatment.

SALMONELLA OUTBREAK - RECALLED EGGS, 95 CASES IN 14 STATES

  • CDC reported August 28, 2025, that 95 people across 14 states became sick from the same Salmonella strain linked to recalled eggs; consumers should check for and discard any recalled product.

LISTERIA OUTBREAK - PREPARED MEALS, ONGOING

  • As of October 30, 2025, CDC continued urging consumers to check refrigerators and freezers for recalled prepared meal products linked to an ongoing Listeria monocytogenes outbreak, warning that illnesses continued despite recalls.

NEW WORLD SCREWWORM - CDC EMERGENCY OPERATIONS CENTER ACTIVATED

  • CDC activated its Emergency Operations Center for a New World Screwworm response on June 12, 2026, reflecting concern about the parasitic fly's potential impact on human and animal health.

INFANT BOTULISM - NARA ORGANICS FORMULA RECALL

  • CDC issued a June 13, 2026, outbreak update urging parents to immediately stop using all Nara Organics Whole Milk Organic Infant Formula linked to infant botulism cases.

This briefing is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider for personal health decisions.

BIOMED PULSE - Next edition: August 20, 2026

📎 Sources

  1. Ebola disease caused by Bundibugyo virus - Democratic Republic… — WHO Disease Outbreak News
  2. Ebola disease caused by Bundibugyo virus, Democratic Republic … — WHO Disease Outbreak News
  3. Ebola disease caused by Bundibugyo virus, Democratic Republic … — WHO Disease Outbreak News
  4. CDC Mobilizes International Response Following Ebola Disease O… — CDC Newsroom
  5. Enhanced Ebola Airport Screening Begins at Washington-Dulles I… — CDC Newsroom
  6. Enhanced Ebola Airport Screening Expands to Atlanta — CDC Newsroom
  7. Ebola disease caused by Bundibugyo virus, Democratic Republic … — WHO Disease Outbreak News
  8. Ebola disease caused by Bundibugyo virus – Democratic Republic… — WHO Disease Outbreak News
  9. Hantavirus outbreak linked to cruise ship travel, Multi-locations — WHO Disease Outbreak News
  10. Hantavirus cluster linked to cruise ship travel, Multi-country — WHO Disease Outbreak News

Curated from official sources — WHO/CDC/ECDC/openFDA/ClinicalTrials.gov/Europe PMC. Informational only — not medical advice.
Serial 20260819-02-v60 · 2026-08-19 02:02 UTC · pulse.uzylab.com

Read next